2010
Pharmacokinetic Interactions Between Buprenorphine/Naloxone and Once-Daily Lopinavir/Ritonavir
Bruce RD, Altice FL, Moody DE, Morse GD, Andrews L, Lin SN, Fang WB, Ma Q, Friedland GH. Pharmacokinetic Interactions Between Buprenorphine/Naloxone and Once-Daily Lopinavir/Ritonavir. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2010, 54: 511-514. PMID: 20672450, PMCID: PMC4841260, DOI: 10.1097/qai.0b013e3181d3cad3.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnalgesics, OpioidAnti-HIV AgentsBuprenorphineDrug InteractionsFemaleHIV InfectionsHumansLopinavirMaleMetabolic Clearance RateMiddle AgedNaloxonePyrimidinonesRitonavirConceptsLPV/rBuprenorphine/naloxoneHIV-seronegative subjectsLopinavir/ritonavirOpioid withdrawalPharmacokinetic interactionsDaily lopinavir/ritonavirDaily LPV/rSteady-state pharmacokinetic evaluationBuprenorphine pharmacokineticsR administrationDosage modificationNaloxone concentrationsHistorical controlsPharmacodynamic responseAUC0-24hBaseline valuesPharmacokinetic evaluationNaloxonePharmacokinetic studySignificant differencesRitonavirNLXCmaxClearance
2006
Drug Interactions between Opioids and Antiretroviral Medications: Interaction between Methadone, LAAM, and Delavirdine
McCance‐Katz E, Rainey PM, Smith P, Morse GD, Friedland G, Boyarsky B, Gourevitch M, Jatlow P. Drug Interactions between Opioids and Antiretroviral Medications: Interaction between Methadone, LAAM, and Delavirdine. American Journal On Addictions 2006, 15: 23-34. PMID: 16449090, DOI: 10.1080/10550490500419029.Peer-Reviewed Original ResearchConceptsDrug interactionsObjective Opioid Withdrawal ScaleSeven-day study periodNon-nucleoside reverse transcriptase inhibitorMini-Mental State ExaminationOpioid withdrawal symptomsOpioid Withdrawal ScaleClinical pharmacology studiesOpioid-dependent individualsReverse transcriptase inhibitorLAAM treatmentMethadone clearanceOpioid pharmacokineticsOpioid therapyOpioid toxicityAntiretroviral medicationsHIV outcomesPharmacodynamic interactionsCardiac toxicityWithdrawal symptomsAdverse symptomsTranscriptase inhibitorWithdrawal ScaleAcetyl methadolPharmacology studies
2005
Population Pharmacokinetics of Delavirdine and N-Delavirdine in HIV-Infected Individuals
Smith PF, DiCenzo R, Forrest A, Shelton M, Friedland G, Para M, Pollard R, Fischi M, DiFrancesco R, Morse GD. Population Pharmacokinetics of Delavirdine and N-Delavirdine in HIV-Infected Individuals. Clinical Pharmacokinetics 2005, 44: 99-109. PMID: 15634033, DOI: 10.2165/00003088-200544010-00004.Peer-Reviewed Original ResearchConceptsLarge interpatient variabilityPharmacokinetic parameter estimatesCombination regimensPopulation pharmacokineticsInterpatient variabilityNon-nucleoside reverse transcriptase inhibitorPopulation pharmacokinetic parameter estimatesCells/mm3Double-blind studyHIV-1 infectionMean apparent volumeAge 37 yearsPopulation pharmacokinetic analysisReverse transcriptase inhibitorVolume of distributionFirst-order clearanceTherapeutic drug monitoringTarget drug concentrationsCD4 countMonotherapy studiesOral clearanceDosage regimensPlasma concentrationsTranscriptase inhibitorPharmacokinetic analysis
1998
Methadone Effects on Zidovudine Disposition (AIDS Clinical Trials Group 262)
McCanceKatz E, Rainey P, Jatlow P, Friedland G. Methadone Effects on Zidovudine Disposition (AIDS Clinical Trials Group 262). JAIDS Journal Of Acquired Immune Deficiency Syndromes 1998, 18: 435-443. PMID: 9715839, DOI: 10.1097/00042560-199808150-00004.Peer-Reviewed Original ResearchConceptsInjection drug usersMethadone treatmentChronic methadone treatmentMethadone-maintained patientsHeroin-addicted patientsMethadone effectsZDV doseZDV exposureZDV pharmacokineticsZDV treatmentZidovudine dispositionZidovudine therapyHIV diseaseMethadone levelsPharmacokinetic interactionsTherapeutic rangeRenal clearanceToxicity surveillanceSide effectsDrug usersDrug efficacyZDVClearanceAUCPatients